TNSN07297A1 - Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes - Google Patents

Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Info

Publication number
TNSN07297A1
TNSN07297A1 TNP2007000297A TNSN07297A TNSN07297A1 TN SN07297 A1 TNSN07297 A1 TN SN07297A1 TN P2007000297 A TNP2007000297 A TN P2007000297A TN SN07297 A TNSN07297 A TN SN07297A TN SN07297 A1 TNSN07297 A1 TN SN07297A1
Authority
TN
Tunisia
Prior art keywords
diabetes
rimonabant
medicaments
prevention
preparation
Prior art date
Application number
TNP2007000297A
Inventor
Corinne Hanotin
Pierre Rosenzweig
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/en
Priority claimed from PCT/FR2006/000376 external-priority patent/WO2006087481A1/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of TNSN07297A1 publication Critical patent/TNSN07297A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of rimonabant, either alone or combined with another active principle, for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes or non-insulin dependent diabetes and/or the complications thereof.
TNP2007000297A 2005-02-21 2007-07-31 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes TNSN07297A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (en) 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
FR0504942A FR2882264A1 (en) 2005-02-21 2005-05-12 Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes
FR0505228A FR2882265B1 (en) 2005-02-21 2005-05-23 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES.
PCT/FR2006/000376 WO2006087481A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
TNSN07297A1 true TNSN07297A1 (en) 2008-12-31

Family

ID=36809538

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000297A TNSN07297A1 (en) 2005-02-21 2007-07-31 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Country Status (10)

Country Link
JP (1) JP2008530189A (en)
BR (1) BRPI0608183A2 (en)
CR (1) CR9293A (en)
EA (1) EA011618B1 (en)
FR (2) FR2882264A1 (en)
IL (1) IL185401A0 (en)
MA (1) MA29262B1 (en)
MX (1) MX2007009996A (en)
TN (1) TNSN07297A1 (en)
TW (1) TW200640457A (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (en) * 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
FR2882265A1 (en) 2006-08-25
JP2008530189A (en) 2008-08-07
MX2007009996A (en) 2007-10-10
MA29262B1 (en) 2008-02-01
FR2882265B1 (en) 2009-02-13
EA011618B1 (en) 2009-04-28
EA200701781A1 (en) 2007-12-28
CR9293A (en) 2007-10-01
BRPI0608183A2 (en) 2009-11-17
TW200640457A (en) 2006-12-01
IL185401A0 (en) 2008-08-07
FR2882264A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
GB2430157A (en) Personal care products and methods for inhibiting the adherence of flora to skin
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
MY148723A (en) Use of pinolenic acid for the treatment of obesity
IL185808A0 (en) Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments
WO2006112716A3 (en) Nutritional supplement for hiv patients
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
EP2241196A3 (en) Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
EP2091540A4 (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
EP1935418A4 (en) Composition for relieving subjective symptoms of fatigue
EP2164490A4 (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2008079993A3 (en) Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
TW200728295A (en) Benzochromene derivatives
MX2007011381A (en) Spirulin composition rich in active principles, method for obtaining same and use thereof.
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
IL185807A0 (en) Use of amino-substituted benzimidazoles
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
MXPA05013121A (en) Indole derivatives with apoptosis-inducing effect.
TNSN07297A1 (en) Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
WO2008008513A3 (en) Combination treatments